Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kinex Pharmaceuticals has begun Phase I human testing for its drug KX2-391, which belongs to an emerging new family of targeted cancer treatments called protein kinase inhibitors.
Subscribe to our email newsletter
Dosing has begun at Roswell Park Cancer Institute in Buffalo, New York, and will commence in the next several days at M.D. Anderson Cancer Center in Houston, Texas. The trial is expected to enroll 50 patients with advanced solid tumors and lymphoma and will evaluate safety, tolerability and pharmacokinetics. Exploratory biomarker studies will also be involved.
Allen Barnett, CEO of Kinex, said: “As we go further in the drug’s development, and do broader testing, we get better and better data. We are extremely enthusiastic about the potential for KX2-391 because it represents a unique approach for the treatment of cancer. It is a first-in-class drug that has the potential to provide patients with a safe and effective treatment for a broad range of tumor types.”